Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry|December 4, 2014
Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitorsWufu Zhu, Chengyu Sun, Shan Xu, et al.Bioorganic & Medicinal Chemistry|December 6, 2017
Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitorsLinxiao Wang, Shan Xu, Xiuying Chen, et al.European Journal of Medicinal Chemistry|November 20, 2023
Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLCSheng Tang, Chuanchuan Sun, Xintao He, et al.Bioorganic Chemistry|October 9, 2022
Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapyXin Sun, Binliang Zhang, Leixuan Luo, et al.Bioorganic & Medicinal Chemistry|June 30, 2016
Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moietyChengyu Sun, Chen Chen, Shan Xu, et al.Bioorganic Chemistry|April 10, 2025
Novel ALK inhibitors containing DAAP fragments: Rational drug design and anti-tumor activity researchRan Wang, Xiangjing Li, Li Long, et al.Journal of Materials Chemistry. B|April 29, 2026
Bio-nano architectures as therapeutic platforms: mechanism-driven precision anti-infective therapy for periodontal regenerationJiawei Du, Shizhe Li, Zishu Wang, et al.European Journal of Medicinal Chemistry|November 7, 2017
Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitorsLin Xiao Wang, Xiaobo Liu, Shan Xu, et al.European Journal of Medicinal Chemistry|May 19, 2018
Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitorsYiqiang OuYang, Wensheng Zou, Liang Peng, et al.BMC Chemistry|August 27, 2024
Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858RLinxiao Wang, Xiaoling Huang, Shidi Xu, et al.Pageof 9